Satellos’ oral DMD drug improves arm movement after six months in Phase II

Phase 2positivePositive

AI Analysis

Summary

Satellos' oral DMD drug demonstrated improved arm movement after six months in a Phase II open-label study, where patients received the drug for an additional 11 months following an earlier 28-day trial.

Clinical Trial Data

Phase

Phase 2

Primary Endpoint

Met

Outcome Details

Oral DMD drug improved arm movement after six months in Phase II open-label study

Importance:6/10

Sentiment:

0.70

DMDoral drugPhase 2arm movementopen-label

Related Companies

$MSCLF

Read the original article

Published by Clinical Trials Arena on July 9, 2026 10:21 AM

Read Original